A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications (NCT04877288)

🧪 Interventions in This Study

• Belatacept (BIOLOGICAL)
• Tacrolimus (DRUG)
• Cyclosporine A (DRUG)
• Mycophenolate Mofetil (DRUG)
• Enteric Coated Mycophenolate Sodium (DRUG)
• Corticosteroids (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Male and female adolescents 12 to less than 18 years of age
2. Recipients of a renal allograft from a living or deceased donor transplanted at least 6 calendar months prior to enrollment
3. Receiving a stable regimen of a calcineurin inhibitor (CNI), with mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium/mycophenolate mofetil (EC-MPS/MPA), with or without daily corticosteroids for ≥ 30 days prior to randomization
4. Clinically stable renal function during the 12-week period prior to screening, in the opinion of the investigator and based on protocol-defined criteria for proteinuria and estimated glomerular filtration rate (eGFR)
5. Serologic evidence of past exposure to Epstein-Barr virus (EBV) and current absence of EBV DNA replication at or prior to renal transplantation and during the Screening period
6. Completion of an initial course of SARS-CoV-2 vaccination per local standard of care, a minimum of 6 weeks prior to enrollment

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (38 Sites)

Showing the first 25 of 38 sites.

• Local Institution - 0042 — Birmingham, Alabama
• Local Institution - 0041 — Los Angeles, California
• Local Institution - 0014 — Washington D.C., District of Columbia
• Local Institution - 0022 — Hollywood, Florida
• Local Institution - 0045 — Miami, Florida
• Local Institution - 0049 — Atlanta, Georgia
• Local Institution - 0033 — Chicago, Illinois
• Local Institution - 0017 — Baltimore, Maryland
• Local Institution - 0044 — Boston, Massachusetts
• Local Institution - 0043 — St Louis, Missouri
• Local Institution - 0024 — Durham, North Carolina
• Local Institution - 0025 — Cincinnati, Ohio
• Local Institution - 0048 — Cleveland, Ohio
• Local Institution - 0052 — Portland, Oregon
• Local Institution - 0038 — Seattle, Washington
• Hospital Italiano de Buenos Aires — ABB, Buenos Aires F.D.
• Local Institution - 0062 — Buenos Aires,
• UZ Gent-Paediatric Nephrology and Rheumatology Department — Ghent,
• Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu — Nantes, Loire-Atlantique
• Bordeaux University Hospital - Pellegrin-Pediatrics — Bordeaux,
• Hospices Civils de Lyon - Hôpital Femme Mère Enfant-néphrologie pédiatrique — Bron,
• Hopital De La Timone — Marseille,
• Hopital Necker — Paris,
• Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universita — Paris,
• Universitaetsklinikum Essen — Essen, North Rhine-Westphalia

📞 Contact the Study Coordinator

Phone: (855) 907-3286

Email: Clinical.Trials@bms.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Renal Allograft Recipients clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.